Genipin inhibits the invasion and migration of colon cancer cells by the suppression of HIF-1α accumulation and VEGF expression

被引:43
作者
Lee, Suk-young [1 ]
Kim, Hong Jun [1 ]
Oh, Sang Cheul [1 ,2 ]
Lee, Dae-Hee [1 ,2 ]
机构
[1] Korea Univ, Dept Oncol, Guro Hosp, 148 Gurodong Gil, Seoul 152703, South Korea
[2] Korea Univ, Coll Med, Grad Sch Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Genipin; Hypoxia-inducible factor-1; Vascular endothelial growth factor; Invasion; Akt; ERK; ENDOTHELIAL GROWTH-FACTOR; JUN NH2-TERMINAL KINASE; HYPOXIA-INDUCED ACCUMULATION; INDUCIBLE FACTOR-I; INDUCED APOPTOSIS; COLORECTAL-CANCER; HEPATOMA-CELLS; PROTEIN; ANGIOGENESIS; GENIPOSIDE;
D O I
10.1016/j.fct.2018.04.005
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) play important roles in cancer progression in various cancer cell lines. Although genipin, a constituent of Gardenia fruit, has been shown to have anti-tumor activity, its role in the suppression of HIF-1 and its downstream target genes is not well understood. We examined the effect of genipin on the intracellular level of HIF-la and extracellular level of VEGF using the colon cancer cell line HCT116. We observed that genipin suppressed the accumulation of HIF-1 alpha under hypoxia in various cancer cell lines, including HCT116, via the modulation of protein degradation. Genipin also suppressed the expression of VEGF and the invasion of colon cancer cells by blocking the extracellular signal-regulated kinase signaling pathway. Taken together, our results provide new insights into the potential role of genipin in suppressing colon cancer progression.
引用
收藏
页码:70 / 76
页数:7
相关论文
共 35 条
[1]  
AKAO T, 1994, BIOL PHARM BULL, V17, P1573
[2]   Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications [J].
Cao, Dan ;
Hou, Mei ;
Guan, Yong-song ;
Jiang, Ming ;
Yang, Yu ;
Gou, Hong-feng .
BMC CANCER, 2009, 9
[3]   Genipin Induced Apoptosis Associated with Activation of the c-Jun NH2-Terminal Kinase and p53 Protein in HeLa Cells [J].
Cao, Houli ;
Feng, Qian ;
Xu, Wei ;
Li, Xiaorong ;
Kang, Zhuang ;
Ren, Yanqin ;
Du, Linfang .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2010, 33 (08) :1343-1348
[4]   Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1α induction in response to hypoxic stress and growth factors [J].
Chau, NM ;
Rogers, P ;
Aherne, W ;
Carroll, V ;
Collins, I ;
McDonald, E ;
Workman, P ;
Ashcroft, M .
CANCER RESEARCH, 2005, 65 (11) :4918-4928
[5]   Urokinase plasminogen activator system - A multifunction role in tumor progression and metastasis [J].
Choong, PFM ;
Nadesapillai, APW .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2003, (415) :S46-S58
[6]   PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a) [J].
Emerling, Brooke M. ;
Weinberg, Frank ;
Liu, Juinn-Lin ;
Mak, Tak W. ;
Chandel, Navdeep S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (07) :2622-2627
[7]   Apigenin inhibits tumor angiogenesis through decreasing HIF-1α and VEGF expression [J].
Fang, Jing ;
Zhou, Qiong ;
Liu, Ling-Zhi ;
Xia, Chang ;
Hu, Xiaowen ;
Shi, Xianglin ;
Jiang, Bing-Hua .
CARCINOGENESIS, 2007, 28 (04) :858-864
[8]   Apoptosis induced by genipin in human leukemia K562 cells: involvement of c-Jun N-terminal kinase in G2/M arrest [J].
Feng, Qian ;
Cao, Hou-li ;
Xu, Wei ;
Li, Xiao-rong ;
Ren, Yan-qin ;
Du, Lin-fang .
ACTA PHARMACOLOGICA SINICA, 2011, 32 (04) :519-527
[9]   The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25
[10]   Chrysin inhibits expression of hypoxia-inducible factor-1α through reducing hypoxia-inducible factor-1α stability and inhibiting its protein synthesis [J].
Fu, Beibei ;
Xue, Jing ;
Li, Zhaodong ;
Shi, Xianglin ;
Jiang, Bing-Hua ;
Fang, Jing .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (01) :220-226